| 前收市價 | 3.3440 |
| 開市 | 3.3300 |
| 買盤 | 3.3960 x 無 |
| 賣出價 | 3.4460 x 無 |
| 今日波幅 | 3.3000 - 3.3700 |
| 52 週波幅 | 2.0560 - 9.1200 |
| 成交量 | |
| 平均成交量 | 35,240 |
| 市值 | 768.982M |
| Beta 值 (5 年，每月) | 2.64 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.2200 |
| 業績公佈日 | 2024年8月15日 - 2024年8月19日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 72.97 |
ZacksCureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?
CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksGSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.
ZacksBiotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
